Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern – ACROFAN USA

TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ — Jiangsu Recbio Technology Co., Ltd. (“Recbio”), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant…

Click here to view the original article.